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The dictum “Primum non nocere” remains axiomatic of
modern clinical practice, yet adverse drug reactions are
accepted as a consequence of drug use despite estimates that
morbidity and mortality resulting from adverse reactions to
drugs is not insignificant (1). At the bedside, an accurate
assessment of a potential adverse drug reaction relies on a
precise diagnosis that in many cases is difficult or impossible
because of several competing risk factors, especially in
patients with complex and/or chronic illness. Thus, a
diagnosis of an adverse drug reaction is often presumptive.
In cardiology, one example of this problem is in determining
whether sulfonylurea drugs (SUDs), used in the treatment
of patients with type 2 diabetes mellitus (T2DM), may have
harmful cardiovascular effects, especially in patients with
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coronary artery disease (CAD) (i.e., two complex and
chronic diseases in association with a poorly defined drug
effect). This is an important issue because T2DM is the
most common chronic disease affecting Western popula-
tions, with an increasing incidence, and is associated with a
high prevalence of CAD (2–4). Moreover, hyperglycemia
per se is an independent risk factor in patients presenting
with acute coronary syndromes (5,6). Therefore, if the use
of SUDs to control hyperglycemia causes only a fractional
increase in absolute risk this would translate into a marked
increase in cardiovascular morbidity and mortality when
spread across such a large number of patients.
The sulfonylurea controversy. Uncertainty regarding the
safety of SUDs arose more than 30 years ago after publica-
tion of the University Group Diabetes Program (UGDP)
trial (7), which randomized patients with T2DM to a
sulfonylurea agent (phenformin or tolbutamide), fixed- and
variable-dose insulin, and placebo, and found an increase in
mortality as a result of cardiovascular causes among patients
taking SUD-type medication compared with patients
treated with insulin or placebo (in whom rates were similar).
Within a decade, advances in single-cell patch-clamp
electrophysiologic techniques led to the discovery of a
metabolism-sensitive channel that was inhibited from open-
ing by high levels of intracellular adenosine triphosphate
(ATP) (8). The channel, known as the ATP-sensitive K
(KATP) channel, also is inhibited from opening by SUDs. In
the pancreas, this is the mechanism through which SUDs
induce the release of insulin (9). However, the KATP
channel also plays an essential role in myocardial resistance
towards metabolic stress (9–16). By also preventing opening
of myocardial KATP channels, SUDs could increase the
consequences of ischemia in the heart. Several lines of
evidence, including many clinical studies, have suggested
this mechanism as a basis for the UGDP findings (9).
Opening of KATP channels underlies ST-segment eleva-
tion during ischemia. Beyond a role in protecting the
myocardium from ischemic insult, the efflux of K through
the opening of KATP channels also is thought to underlie
elevation of the ST-segment of the surface electrocardio-
gram (ECG) as a consequence of myocardial injury. Evi-
dence for this initially came from experiments using epicar-
dial recordings in open-chest dogs (17) and in humans
during coronary angioplasty (18). More definitively, in an
elegant series of experiments, Suzuki et al. (19) “knocked-
out” the gene that encodes for Kir6.2, the pore-forming
subunit of sarcolemmal KATP (sKATP, through which K

cross the lipophilic cell membrane), in mouse cardiomyo-
cytes and demonstrated that homozygous knockout (result-
ing in functional absence of sKATP channels) was associated
with the loss of manifest ST-segment elevation, in response
to repeated coronary ligation, readily apparent in wild-type
(control) mice in which the pore-forming region of the
KATP channel was intact. Of note, pretreatment of control
mice with glibenclamide (a SUD) resulted in near-identical
attenuation of the magnitude of ST-segment elevation to
that observed in knockout mice.
Currently, in this issue of the Journal, Huizar et al. (20)
provide, for the first time, evidence that SUDs may atten-
uate the magnitude of ST-segment elevation in patients
presenting with acute myocardial infarction (AMI), leading
to less frequent use of thrombolytic therapy. Because precise
recognition of ST-segment elevation is central to accurate
and efficient triage of patients with chest pain syndromes,
any reduction in its magnitude, for a given degree of
ischemia, limits the power of the ECG as a diagnostic tool.
If proven, the findings of Huizar et al. (20) are important
and should be cause for concern because, whether because of
delayed or misdiagnosis, diabetic patients admitted to
MetroWest Medical Center while on SUDs were much less
likely to receive thrombolytic therapy compared with dia-
betics not taking SUDs (26% vs. 47%) (20).
The study by Huizar et al. (20) does, however, suffer from
several limitations, many of which are acknowledged. First,
it is small and retrospective. Second, all data were derived
from chart review with the assumption that patients as-
signed to the SUD group had taken the drug close enough
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to admission, when the index ECG was performed, to have
any measurable effect (drug levels were not drawn). Third,
on the basis of demographic data presented in Table 1 of
Huizar et al. (20), the control group is far more heteroge-
neous when compared with the study group, especially in
terms of gender distribution (see the following text): more
than one-half the patients were on no therapy or controlled
with diet alone whereas the remainder were mostly taking
insulin (presumably because they were not adequately con-
trolled on oral agents or had type 1 [insulin-dependent]
diabetes). Such differences are important because diabetes
mellitus is a complex disease and not merely a disorder of
elevated blood sugar. As a consequence, intrinsic differences
between the groups are difficult to adjust for (even in much
larger studies) and thus limit meaningful comparison de-
spite broadly similar demographics, blood glucose, and
glycosylated Hb levels at the time of admission. Fourth,
close to 40% of patients initially eligible were excluded from
further analysis. However, all were due to conditions known
to distort the surface ECG, in particular the ST/T portion
(such as bundle branch block, fully paced rhythm, left
ventricular hypertrophy with “strain pattern,” and digoxin
therapy), making ECG interpretation in any case difficult or
impossible and, therefore, are reasonable. It would, how-
ever, have been interesting to know whether the use of more
sensitive markers of myocardial injury, such as cardiac
troponins, or comparison of serial ECG recordings, as is
common in clinical practice, could have impacted on the low
rate of reperfusion therapy administered to study group
patients. Finally, differences in the magnitude of ST-
segment elevation in the control and study groups, although
statistically significant, are, at least in clinical terms, small
(1.1  1.0 mm vs. 2.1  2.7 mm) with a considerable
overlap, making it difficult to see how this alone could
account for the much less frequent use of thrombolysis in
patients treated with SUDs.
To further analyze and compare each group, patients
were arbitrarily grouped according to peak creatine phos-
phokinase (CPK) (CPK 500, 500 to 1,000, and 1,000
mg/dl) levels. When stratified in this way, differences in the
number of nondiagnostic ST-segment elevations were sig-
nificant only in those patients who had moderate infarcts
(CPK 500 to 1,000 mg/dl; p  0.04). This observation,
however, was based on data from only 16 patients (7 in the
SUD group and 9 in the control group). No differences were
found in the number of nondiagnostic ECGs in patients
with small infarcts (CPK 500 mg/dl) or large infarcts
(CPK 1,000 mg/dl). Leaving aside the poor specificity of
CPK as an index of infarct size, looked at another way, 80%
of patients in the SUD group had a peak CPK 1,000
mg/dl (mostly in the range of 500 mg/dl) compared with
58% of patients in the control group. Moreover, patients not
on SUDs were more than twice as likely to suffer a large
infarct (CPK 1,000 mg/dl) compared with patients on
SUDs (41% vs. 20%). Although the authors offer their own
interpretation, our view is that these data, at best, contradict
the notion that SUDs are harmful but more likely simply
expose the pitfalls in drawing conclusions using data derived
from “soft” end points in small groups of patients.
The preponderance of females in the study group (52%
vs. 25%) also deserves comment. Recently, in animal studies
it has been reported that the density of sKATP channels is
significantly higher in females and that this gender differ-
ence declines with ageing (21,22). If this is also the case in
humans, it could, at least in part, account for the greater
attenuation of the ST-segment observed in the SUD group.
One intriguing possibility is whether differences in the
density of sKATP might play some part in gender differences
in regards to outcome after AMI.
Outcomes in T2DM: impact of SUDs? Therefore, given
the hypothesis that SUD may abolish important cardiopro-
tective mechanisms as well as decrease the magnitude of
ST-segment elevation leading to less frequent use of throm-
bolysis, especially in a group of patients known to benefit
from reperfusion therapy (23,24), it is perhaps logical to
assume that SUD use would be associated with worse
outcome, as was observed in the UGDP trial (7). For the
most part, however, available literature does not bear this
out. For example, the United Kingdom Prospective Diabe-
tes Study Group (UKPDS) followed-up 3,867 newly diag-
nosed patients with T2DM randomly assigned to intensive
treatment (with a SUD or insulin) or conventional treat-
ment (25). Over more than 10 years, the use of SUDs was
not associated with increased mortality (a caveat is all
patients enrolled in UKPDS were65 years of age [median
age 54 years] and none had a history of cardiac disease).
Similarly, in a study of patients discharged after AMI, the
use of a SUD was not associated with increased mortality,
although most underwent complete revascularization before
dismissal (26). Several other clinical studies have reported
similar findings (9).
In contrast, Garratt et al. (27) reported that SUDs did
adversely affect outcome among diabetics undergoing direct
angioplasty in the setting of AMI (27). In that study, the
risk of death was found to be 2.77 times higher in the
diabetics taking SUDs, and SUDs were independently
predictive of worse outcome (odds ratio 2.53, 95% confi-
dence interval 1.13 to 5.66). Indeed, the impact of SUD use
in that study was similar to an ejection fraction30% or the
presence of congestive heart failure at admission. However,
in all patients in whom revascularization was successful,
long-term outcome was not affected by SUD use (27). One
explanation for these findings is that KATP channel activa-
tion also protects against microvascular injury, a cause of the
“no-reflow” phenomenon (28). Therefore, exacerbation of
the no-reflow phenomenon by SUDs during coronary
interventions could contribute to worse outcome.
Based on these, as well as other data (9), the cardiovas-
cular consequences of SUDs seem paradoxical. However,
such a dual action of SUD is consistent with several lines of
evidence that suggest that the efficacy with which SUDs
inhibit KATP channels is altered by the extent of cellular
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hypoxia (29–31). Putting this in clinical terms, the conse-
quence of SUD use appears to be determined in large part
by the presence or absence of myocardial ischemia.
Optimal management of T2DM, CAD, and SUDs in
2003? Using this model, whereby the harmful cardiovascu-
lar effects of SUDs relate to the presence or absence of
myocardial ischemia, together with the findings of Huizar et
al. (20), what is then the most appropriate management of
diabetic patients who present with suspected acute coronary
syndrome while taking SUDs? Unfortunately, a definitive
answer to this question is not yet possible, especially in light
of the fact that the issues surrounding the management of
the diabetic patient are complex and often controversial
(24). Clearly, given the potential for SUDs to reduce the
sensitivity of the ECG, as reported by Huizar et al (20),
increased awareness, along with greater vigilance when
assessing diabetic patients, is important. In regards to
controlling hyperglycemia, our view, in the spirit of “first do
no harm” and until more definitive data are available, is that
SUDs should immediately be discontinued and insulin
infusion substituted where necessary. This may also have
beneficial effects beyond stopping the SUDs (24,32). Sub-
sequently, after myocardial ischemia has been ruled out, or
treated, the SUDs can safely be restarted. Such an approach
is safe, simple, and inexpensive.
In response to the question, “the sulfonylurea controversy:
much ado about nothing or cause for concern?,” our view is
that this important issue has yet to be satisfactorily resolved.
Until then, and in light of the potential for harm, the
cardiovascular effects of SUDs should remain a cause for
concern to cardiologists as well as to other physicians caring
for patients with T2DM and CAD. The study by Huizar et
al. (20) surely adds to the debate, as well as highlighting the
urgent need for adequately powered randomized trials, in
hopes of putting to rest more than a quarter century of
uncertainty regarding the safe use of SUDs (9).
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